Friday, November 15, 2024
HomeNews

News

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

Protagonist Therapeutics announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC). Also Read: Glass Lewis Proxy...

Biocytogen Signs RenMab/RenLite Licensing Agreement with BeiGene

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. for licensing Biocytogen's fully human antibody RenMab/RenLite mice platforms to...

CoNextions TR Tendon Repair System Receives FDA Clearance

CoNextions Inc. , an innovator in tendon repair, is pleased to announce that CoNextions TR Tendon Repair System has received FDA 510(k) Clearance. Expected...

Ubie, Japanese HealthTech Startup, Launches AI-powered Symptom Checker in U.S.

Ubie, Inc., a healthcare AI startup with the mission "To develop a healthcare guide for everyone," has launched in the United States an "AI-powered...

TeDan Surgical Innovations Redefines Anterior to the Psoas Access with the Release of the Phantom UL ATP Surgical Access System

TeDan Surgical Innovations (TSI), leader in the development and commercialization of surgical access systems continues to address evolving surgical access techniques to the spine...
0FansLike
0FollowersFollow
spot_img

Hot Topics